Dana Gitnick

Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.

D. K. Treiber, Zdravko V. Milanov, R. Armstrong, 2011, Bioorganic & medicinal chemistry letters.

CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity

Raffaella Faraoni, Darren E. Insko, P. Dobrzanski, 2012, Molecular Cancer Therapeutics.

Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases.

D. K. Treiber, Brian T. Campbell, R. Armstrong, 2012, ACS medicinal chemistry letters.

Preclinical Development CEP-32496 : A Novel Orally Active BRAFV 600 E Inhibitor with Selective Cellular and In Vivo Antitumor Activity

Raffaella Faraoni, Darren E. Insko, P. Dobrzanski, 2012 .

Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors.

P. Zarrinkar, Darren E. Insko, R. Armstrong, 2015, Bioorganic & medicinal chemistry letters.

Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.

A. Ghose, Brian T. Campbell, Raffaella Faraoni, 2012, Journal of medicinal chemistry.

4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors.

Brian T. Campbell, Raffaella Faraoni, Andiliy G. Lai, 2011, Bioorganic & Medicinal Chemistry Letters.

Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.

A. Ghose, Brian T. Campbell, Raffaella Faraoni, 2012, Journal of medicinal chemistry.